Meningitis B Vaccine Fails to Prevent Gonorrhoea in Men, Large Study Finds

New research has cast doubt on the efficacy of the Meningitis B (MenB) vaccine as a preventative measure against gonorrhoea in men. Despite earlier suggestions of a potential cross-protection, a large-scale study involving thousands of individuals has found no evidence that the vaccine reduces the risk of contracting the sexually transmitted infection.

Previously, observational data had indicated a possible association between MenB vaccination and a reduced incidence of gonorrhoea. This led some health organisations to consider its potential off-label use, particularly for at-risk male populations, as an auxiliary strategy in combating the rise of antibiotic-resistant gonorrhoea strains.

However, the latest findings, which tracked vaccinated and unvaccinated cohorts over an extended period, demonstrate a clear lack of impact. The study concluded that men who received the MenB vaccine were no less likely to be diagnosed with gonorrhoea than their unvaccinated counterparts. This necessitates a re-evaluation of public health strategies that might have considered the MenB vaccine as a supplementary tool in gonorrhoea prevention.

The emphasis remains on established methods of prevention, including consistent condom use and regular sexual health screenings, especially as challenges in treating drug-resistant strains of gonorrhoea continue to intensify.